Table 2. Expression of LAG-3 by... | American Society of Hematology

Table 2.

Expression of LAG-3 by tumor-infiltrating lymphocytes in malignant HL lymph nodes

Case no.	Disease status	Age at diagnosis, y/sex	Histology	LAG-3⁺ cells in HRS-positive regions*	EBV tissue status
2	ND	45/F	MC	+++	Negative
8	ND	30/F	NS	++	Negative
18	RL	44/M	NS	++	Negative
22	Remission	48/M	NS	-	Negative
28	ND	21/F	NS	+	Negative
31	ND	76/M	NS	++	Negative
32	ND	30/M	NS	++	Positive
33	ND	26/M	NS	+	Negative
35	ND	48/F	NS	++	Positive
36	RL	34/F	NS	-	Positive
38	Remission	33/M	NS	-	Positive
40	ND	25/M	NS	+	Positive
44	ND	22/F	NS	+	Positive
47	ND	29/M	MC	++	Negative
48	Remission	35/F	MC	+++	Positive
49	ND	45/F	MC	++	Negative
50	Remission	21/M	NS	+	Negative
51	RL	25/F	NS	-	Negative
53	ND	22/M	MC	++	Positive
54	Remission	24/F	NS	-	Negative
55	Remission	42/M	NLP	+	Negative
56	ND	20/M	MC	+++	Positive
57	ND	21/F	MC	+++	Positive
64	ND	43/M	NS	++	Positive
65	RL	56/M	NS	+	Negative
67	ND	13/F	MC	+++	Positive
69	RL	34/F	NS	+	Negative
70	ND	24/M	NS	++	Negative
71	RL	31/F	NS	+	Negative
72	ND	26/M	NS	-	Negative
74	ND	34/M	NS	++	Negative
76	ND	23/M	NS	+	Negative
77	ND	36/M	NS	++	Negative
78	ND	21/M	NS	-	Negative
79	ND	26/M	NS	+++	Positive
80	ND	34/M	LR	+++	Negative
81	ND	28/M	NS	++	Positive
82	ND	36/F	NS	++	Negative
83	ND	29/F	NS	++	Negative
84	ND	23/F	NS	++	Positive
85	ND	59/M	NS	+++	Negative
86	ND	20/M	NLP	++	Negative
88	ND	19/F	NS	-	Negative

Case no.	Disease status	Age at diagnosis, y/sex	Histology	LAG-3⁺ cells in HRS-positive regions*	EBV tissue status
2	ND	45/F	MC	+++	Negative
8	ND	30/F	NS	++	Negative
18	RL	44/M	NS	++	Negative
22	Remission	48/M	NS	-	Negative
28	ND	21/F	NS	+	Negative
31	ND	76/M	NS	++	Negative
32	ND	30/M	NS	++	Positive
33	ND	26/M	NS	+	Negative
35	ND	48/F	NS	++	Positive
36	RL	34/F	NS	-	Positive
38	Remission	33/M	NS	-	Positive
40	ND	25/M	NS	+	Positive
44	ND	22/F	NS	+	Positive
47	ND	29/M	MC	++	Negative
48	Remission	35/F	MC	+++	Positive
49	ND	45/F	MC	++	Negative
50	Remission	21/M	NS	+	Negative
51	RL	25/F	NS	-	Negative
53	ND	22/M	MC	++	Positive
54	Remission	24/F	NS	-	Negative
55	Remission	42/M	NLP	+	Negative
56	ND	20/M	MC	+++	Positive
57	ND	21/F	MC	+++	Positive
64	ND	43/M	NS	++	Positive
65	RL	56/M	NS	+	Negative
67	ND	13/F	MC	+++	Positive
69	RL	34/F	NS	+	Negative
70	ND	24/M	NS	++	Negative
71	RL	31/F	NS	+	Negative
72	ND	26/M	NS	-	Negative
74	ND	34/M	NS	++	Negative
76	ND	23/M	NS	+	Negative
77	ND	36/M	NS	++	Negative
78	ND	21/M	NS	-	Negative
79	ND	26/M	NS	+++	Positive
80	ND	34/M	LR	+++	Negative
81	ND	28/M	NS	++	Positive
82	ND	36/F	NS	++	Negative
83	ND	29/F	NS	++	Negative
84	ND	23/F	NS	++	Positive
85	ND	59/M	NS	+++	Negative
86	ND	20/M	NLP	++	Negative
88	ND	19/F	NS	-	Negative

There was a significant correlation between percent LAG-3 staining and MC and/or LR histology versus NS (r = 0.555, P < .001) and between LAG-3 and positive EBV status (r = 0.31, P = .036).

ND indicates newly diagnosed; MC, mixed cellularity; NS, nodular sclerosing); RL, relapsed; Remission, long-term remission; NLP, nodular lymphocyte predominant; and LR, lymphocyte rich.

Percentage of non-HRS cells within HRS-rich areas that are positive for LAG-3; +++ indicates 74% to 50%; ++, 49% to 25%; +, 24% to 10%; -, less than 10%.

View Large

This Feature Is Available To Subscribers Only